RU2007121850A - Производные фосфонооксихиназолина и их фармацевтическое применение - Google Patents
Производные фосфонооксихиназолина и их фармацевтическое применение Download PDFInfo
- Publication number
- RU2007121850A RU2007121850A RU2007121850/04K RU2007121850K RU2007121850A RU 2007121850 A RU2007121850 A RU 2007121850A RU 2007121850/04 K RU2007121850/04 K RU 2007121850/04K RU 2007121850 K RU2007121850 K RU 2007121850K RU 2007121850 A RU2007121850 A RU 2007121850A
- Authority
- RU
- Russia
- Prior art keywords
- amino
- acetamide
- pyrazol
- quinazolin
- propoxy
- Prior art date
Links
- -1 2,3-difluorophenyl Chemical group 0.000 claims abstract 13
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims abstract 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- WWZCTHYYRVAJIG-NRFANRHFSA-N n-(3-fluorophenyl)-2-[3-[[7-[3-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound OC[C@@H]1CCCN1CCCOC1=CC=C(C(NC2=NNC(CC(=O)NC=3C=C(F)C=CC=3)=C2)=NC=N2)C2=C1 WWZCTHYYRVAJIG-NRFANRHFSA-N 0.000 claims abstract 4
- XQWUFPUUHVVAIM-UHFFFAOYSA-N n-(3-fluorophenyl)-2-[3-[[7-[3-[2-hydroxyethyl(propyl)amino]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound N=1C=NC2=CC(OCCCN(CCO)CCC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 XQWUFPUUHVVAIM-UHFFFAOYSA-N 0.000 claims abstract 3
- ZGBRLIPLHRQLPB-IBGZPJMESA-N n-(2,3-difluorophenyl)-2-[3-[[7-[3-[(2s)-2-(2-hydroxyethyl)pyrrolidin-1-yl]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound OCC[C@@H]1CCCN1CCCOC1=CC=C(C(NC2=NNC(CC(=O)NC=3C(=C(F)C=CC=3)F)=C2)=NC=N2)C2=C1 ZGBRLIPLHRQLPB-IBGZPJMESA-N 0.000 claims abstract 2
- ZNGNLXZBVWXEKM-SFHVURJKSA-N n-(2,3-difluorophenyl)-2-[3-[[7-[3-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound OC[C@@H]1CCCN1CCCOC1=CC=C(C(NC2=NNC(CC(=O)NC=3C(=C(F)C=CC=3)F)=C2)=NC=N2)C2=C1 ZNGNLXZBVWXEKM-SFHVURJKSA-N 0.000 claims abstract 2
- WWZCTHYYRVAJIG-OAQYLSRUSA-N n-(3-fluorophenyl)-2-[3-[[7-[3-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound OC[C@H]1CCCN1CCCOC1=CC=C(C(NC2=NNC(CC(=O)NC=3C=C(F)C=CC=3)=C2)=NC=N2)C2=C1 WWZCTHYYRVAJIG-OAQYLSRUSA-N 0.000 claims abstract 2
- 239000010802 sludge Substances 0.000 claims 3
- IBBRPNCDYSSTKO-UHFFFAOYSA-N 2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-fluoroquinazolin-4-yl]amino]-1h-pyrazol-5-yl]-n-(3-fluorophenyl)acetamide Chemical compound C=12C=C(F)C(OCCCN(CCO)CC)=CC2=NC=NC=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 IBBRPNCDYSSTKO-UHFFFAOYSA-N 0.000 claims 2
- UHVRUAQUBZYULG-UHFFFAOYSA-N 2-[3-[[7-[3-[ethyl(3-hydroxypropyl)amino]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]-n-(3-fluorophenyl)acetamide Chemical compound N=1C=NC2=CC(OCCCN(CCCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 UHVRUAQUBZYULG-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QAXMKRUYFZMQME-UHFFFAOYSA-N 2-[3-[[7-[3-[butyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]-n-(2,3-difluorophenyl)acetamide Chemical compound N=1C=NC2=CC(OCCCN(CCO)CCCC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1F QAXMKRUYFZMQME-UHFFFAOYSA-N 0.000 claims 1
- ZZQPWSQANDNNMJ-UHFFFAOYSA-N 2-[3-[[7-[3-[cyclopentyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]-n-(2,3-difluorophenyl)acetamide Chemical compound C1CCCC1N(CCO)CCCOC(C=C1N=CN=2)=CC=C1C=2NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1F ZZQPWSQANDNNMJ-UHFFFAOYSA-N 0.000 claims 1
- PIJGHCNBBRXNDH-UHFFFAOYSA-N 2-[3-[[7-[3-[cyclopentyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]-n-(3-fluorophenyl)acetamide Chemical compound C1CCCC1N(CCO)CCCOC(C=C1N=CN=2)=CC=C1C=2NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 PIJGHCNBBRXNDH-UHFFFAOYSA-N 0.000 claims 1
- FJSLAMFWWZCIJT-LJQANCHMSA-N n-(2,3-difluorophenyl)-2-[3-[[7-[4-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]butoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound OC[C@H]1CCCN1CCCCOC1=CC=C(C(NC2=NNC(CC(=O)NC=3C(=C(F)C=CC=3)F)=C2)=NC=N2)C2=C1 FJSLAMFWWZCIJT-LJQANCHMSA-N 0.000 claims 1
- FJSLAMFWWZCIJT-IBGZPJMESA-N n-(2,3-difluorophenyl)-2-[3-[[7-[4-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]butoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound OC[C@@H]1CCCN1CCCCOC1=CC=C(C(NC2=NNC(CC(=O)NC=3C(=C(F)C=CC=3)F)=C2)=NC=N2)C2=C1 FJSLAMFWWZCIJT-IBGZPJMESA-N 0.000 claims 1
- CJXGFQJYVYILDY-UHFFFAOYSA-N n-(2,3-difluorophenyl)-2-[3-[[7-[[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound C1CN(CCO)CCC1COC1=CC=C(C(NC2=NNC(CC(=O)NC=3C(=C(F)C=CC=3)F)=C2)=NC=N2)C2=C1 CJXGFQJYVYILDY-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- NPIAVEXGKZDDRP-UHFFFAOYSA-N n-(2,3-difluorophenyl)-2-[3-[[7-[3-[(4-hydroxy-2-methylbutan-2-yl)amino]propoxy]quinazolin-4-yl]amino]-1h-pyrazol-5-yl]acetamide Chemical compound N=1C=NC2=CC(OCCCNC(C)(CCO)C)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1F NPIAVEXGKZDDRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.Соединение, выбранное из любого следующего соединения:N-(2,3-дифторфенил)-2-{3-[(7-{[1-(2-гидроксиэтил)пиперидин-4-ил]метокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(2,3-дифторфенил)-2-{3-[(7-{3-[(3-гидрокси-1,1-диметилпропил)амино]пропокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(2,3-дифторфенил)-2-{3-[(7-{3-[(2S)-2-(2-гидроксиэтил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(2,3-дифторфенил)-2-{3-[(7-{3-[(2-гидроксиэтил)(бутил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;2-{3-[(7-{3-[циклопентил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-(2,3-дифторфенил)ацетамида;N-(2,3-дифторфенил)-2-{3-[(7-{3-[(2S)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(3-фторфенил)-2-{3-[(7-{3-[(2S)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;2-{3-[(7-{3-[циклопентил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-фторфенил)ацетамида;N-(3-фторфенил)-2-{3-[(7-{3-[этил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(3-фторфенил)-2-{3-[(7-{3-[(2-гидрокси-1,1-диметилэтил)амино]пропокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(3-фторфенил)-2-{3-[(7-{3-[(2-гидроксиэтил)(пропил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(3-фторфенил)-2-{3-[(7-{3-[(2R)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(2,3-дифторфенил)-2-{3-[(7-{4-[(2-гидроксиэтил)(пропил)амино]бутокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(3-фторфенил)-2-{3-[(7-{4-[этил(2-гидроксиэтил)амино]бутокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;N-(2,3-дифторфенил)-2-{3-[(7-{4-[(2R)-2-(гидроксиметил)пирролидин-1-ил]бутокси}-хиназо�
Claims (3)
1.Соединение, выбранное из любого следующего соединения:
N-(2,3-дифторфенил)-2-{3-[(7-{[1-(2-гидроксиэтил)пиперидин-4-ил]метокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{3-[(3-гидрокси-1,1-диметилпропил)амино]пропокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{3-[(2S)-2-(2-гидроксиэтил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{3-[(2-гидроксиэтил)(бутил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
2-{3-[(7-{3-[циклопентил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-(2,3-дифторфенил)ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{3-[(2S)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2S)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
2-{3-[(7-{3-[циклопентил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-фторфенил)ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[этил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2-гидрокси-1,1-диметилэтил)амино]пропокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2-гидроксиэтил)(пропил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2R)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{4-[(2-гидроксиэтил)(пропил)амино]бутокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{4-[этил(2-гидроксиэтил)амино]бутокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{4-[(2R)-2-(гидроксиметил)пирролидин-1-ил]бутокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{4-[(2-гидроксиэтил)(метил)амино]бутокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(2,3-дифторфенил)-2-{3-[(7-{4-[(2S)-2-(гидроксиметил)пирролидин-1-ил]бутокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
2-{3-[(7-{3-[этил(3-гидроксипропил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-(3-фторфенил)ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2-гидроксиэтил)(2-метоксиэтил)амино]пропокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида; и
2-{3-[(7-{3-[этил(2-гидроксиэтил)амино]пропокси}-6-фторхиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-(3-фторфенил)ацетамида;
или его фармацевтически приемлемая соль.
2. Соединение, выбранное из любого следующего соединения:
N-(3-фторфенил)-2-{3-[(7-{3-[(2S)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
2-{3-[(7-{3-[циклопентил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-(3-фторфенил)ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[этил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1Н-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2-гидрокси-1,1-диметилэтил)амино]пропокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2-гидроксиэтил)(пропил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{3-[(2S)-2-(гидроксиметил)пирролидин-1-ил]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
N-(3-фторфенил)-2-{3-[(7-{4-[этил(2-гидроксиэтил)амино]бутокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида;
2-{3-[(7-{3-[этил(3-гидроксипропил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-(3-фторфенил)ацетамида;
N-{3-фторфенил)-2-{3-[(7-{3-[(2-гидроксиэтил)(2-метоксиэтил)амино]пропокси}хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамида; и
2-{3-[(7-{3-[этил(2-гидроксиэтил)амино]пропокси}-6-фторхиназолин-4-ил)амино]-1H-пиразол-5-ил}-N-(3-фторфенил)ацетамида;
или его фармацевтически приемлемая соль.
3. N-(3-фторфенил)-2-{3-[(7-{3-[этил(2-гидроксиэтил)амино]пропокси}-хиназолин-4-ил)амино]-1H-пиразол-5-ил}ацетамид.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02293238.8 | 2002-12-24 | ||
EP02293238 | 2002-12-24 | ||
EP03291315.4 | 2003-06-02 | ||
EP03291315 | 2003-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007121850A true RU2007121850A (ru) | 2008-12-20 |
Family
ID=32683824
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007121850/04A RU2350611C1 (ru) | 2002-12-24 | 2003-12-22 | Производные фосфонооксихиназолина и их фармацевтическое применение |
RU2005123485/04A RU2357971C2 (ru) | 2002-12-24 | 2003-12-22 | Производные фосфонооксихиназолина и их фармацевтическое применение |
RU2007121850/04K RU2007121850A (ru) | 2002-12-24 | 2007-06-13 | Производные фосфонооксихиназолина и их фармацевтическое применение |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007121850/04A RU2350611C1 (ru) | 2002-12-24 | 2003-12-22 | Производные фосфонооксихиназолина и их фармацевтическое применение |
RU2005123485/04A RU2357971C2 (ru) | 2002-12-24 | 2003-12-22 | Производные фосфонооксихиназолина и их фармацевтическое применение |
Country Status (30)
Country | Link |
---|---|
US (4) | US7528121B2 (ru) |
EP (2) | EP1578755B1 (ru) |
JP (3) | JP4422102B2 (ru) |
KR (1) | KR101010299B1 (ru) |
AR (2) | AR042668A1 (ru) |
AT (2) | ATE370958T1 (ru) |
AU (1) | AU2003290313B2 (ru) |
BR (1) | BRPI0317717B8 (ru) |
CA (1) | CA2511613C (ru) |
CL (1) | CL2003002731A1 (ru) |
CY (2) | CY1107775T1 (ru) |
DE (2) | DE60328735D1 (ru) |
DK (2) | DK1847539T3 (ru) |
ES (2) | ES2290529T3 (ru) |
HK (2) | HK1080481A1 (ru) |
IL (2) | IL169112A (ru) |
IS (2) | IS2504B (ru) |
MX (1) | MXPA05006918A (ru) |
MY (2) | MY147761A (ru) |
NO (2) | NO335193B1 (ru) |
NZ (1) | NZ540698A (ru) |
PL (2) | PL221490B1 (ru) |
PT (2) | PT1847539E (ru) |
RU (3) | RU2350611C1 (ru) |
SA (1) | SA04240504B1 (ru) |
SI (2) | SI1847539T1 (ru) |
TW (2) | TWI336327B (ru) |
UA (1) | UA83814C2 (ru) |
UY (1) | UY28149A1 (ru) |
WO (1) | WO2004058781A1 (ru) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1463506T3 (da) * | 2001-12-24 | 2010-01-11 | Astrazeneca Ab | Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser |
JP2006516138A (ja) * | 2002-12-24 | 2006-06-22 | アストラゼネカ アクチボラグ | キナゾリン化合物 |
ES2290529T3 (es) * | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
CL2004000797A1 (es) * | 2003-04-16 | 2005-05-27 | Astrazeneca Ab | Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc |
AU2004247626B8 (en) * | 2003-05-15 | 2011-05-19 | Arqule, Inc. | Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38 |
ATE401080T1 (de) * | 2003-06-02 | 2008-08-15 | Astrazeneca Ab | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs |
WO2006040520A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives |
JP2008515961A (ja) * | 2004-10-12 | 2008-05-15 | アストラゼネカ アクチボラグ | 癌に対する使用のためのキナゾリン誘導体 |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8178672B2 (en) * | 2004-10-19 | 2012-05-15 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
US7501430B2 (en) * | 2006-04-17 | 2009-03-10 | Arqule, Inc. | RAF inhibitors and their uses |
GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
GB0609617D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Process & intermediate |
MX2009003793A (es) | 2006-10-09 | 2009-12-14 | Takeda Pharmaceutical | Inhibidores de cinasa. |
WO2009111028A1 (en) * | 2008-03-04 | 2009-09-11 | Vitae Pharmaceuticals, Inc. | Aurora kinase inhibitors |
WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
CA2722220C (en) | 2008-04-30 | 2016-06-07 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
JP2011526912A (ja) * | 2008-07-03 | 2011-10-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | プロテインキナーゼ阻害剤としてのナフチリジノン |
US20100183600A1 (en) * | 2008-12-05 | 2010-07-22 | Arqule, Inc. | RAF Inhibitors and Their Uses |
CA2746652C (en) | 2008-12-11 | 2018-03-06 | Axcentua Pharmaceuticals Ab | Crystalline forms of genistein |
US7863325B2 (en) | 2008-12-11 | 2011-01-04 | Axcentua Pharmaceuticals Ab | Crystalline genistein sodium salt dihydrate |
CA2747326C (en) | 2008-12-22 | 2017-05-16 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
BR112013022307A2 (pt) | 2011-03-04 | 2020-09-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | aminoquinolinas como inibidores de quinase |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
ES2654100T3 (es) * | 2013-02-21 | 2018-02-12 | Glaxosmithkline Intellectual Property Development Limited | Quinazolinas como inhibidores de quinasa |
CN105555315B (zh) * | 2013-09-16 | 2019-05-07 | 阿斯利康(瑞典)有限公司 | 治疗性聚合物纳米颗粒及其制备和使用方法 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2015085289A1 (en) | 2013-12-06 | 2015-06-11 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
EP3678668B1 (en) | 2017-09-08 | 2024-01-10 | The Board of Trustees of the Leland Stanford Junior University | Enpp1 inhibitors and their use for the treatment of cancer |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
WO2020049208A1 (es) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
CN112939948B (zh) * | 2019-12-11 | 2022-05-17 | 苏州美诺医药科技有限公司 | 新型含喹唑啉类化合物及其中间体与应用 |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
WO2022192139A1 (en) | 2021-03-10 | 2022-09-15 | Astrazeneca Ab | Aurora kinase b inhibitors for use for treating cancer |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU2737295A (en) | 1994-06-09 | 1996-01-04 | Glaxo Group Limited | Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (ru) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
JP3944241B2 (ja) | 1995-12-18 | 2007-07-11 | スージェン・インコーポレーテッド | Aur―1および/またはaur―2関連疾患の診断および処置 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
DK0885198T3 (da) | 1996-03-05 | 2002-03-25 | Astrazeneca Ab | 4-Anilinoquinazolinderivater |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ES2241324T3 (es) | 1998-10-08 | 2005-10-16 | Astrazeneca Ab | Derivados de quinazolina. |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
CN1391562A (zh) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
MXPA02011974A (es) | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Derivados de quinazolina sustituidos y su uso como inhibidores. |
AU2001266233B2 (en) | 2000-07-07 | 2006-06-29 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2003000188A2 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
GB0124299D0 (en) * | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
DK1463506T3 (da) | 2001-12-24 | 2010-01-11 | Astrazeneca Ab | Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser |
JP2006516138A (ja) * | 2002-12-24 | 2006-06-22 | アストラゼネカ アクチボラグ | キナゾリン化合物 |
ES2290529T3 (es) * | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
CL2004000797A1 (es) * | 2003-04-16 | 2005-05-27 | Astrazeneca Ab | Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc |
-
2003
- 2003-12-22 ES ES03782672T patent/ES2290529T3/es not_active Expired - Lifetime
- 2003-12-22 KR KR1020057012015A patent/KR101010299B1/ko active IP Right Grant
- 2003-12-22 SI SI200331673T patent/SI1847539T1/sl unknown
- 2003-12-22 EP EP03782672A patent/EP1578755B1/en not_active Expired - Lifetime
- 2003-12-22 DE DE60328735T patent/DE60328735D1/de not_active Expired - Lifetime
- 2003-12-22 NZ NZ540698A patent/NZ540698A/en not_active IP Right Cessation
- 2003-12-22 MY MYPI20071321A patent/MY147761A/en unknown
- 2003-12-22 JP JP2005509716A patent/JP4422102B2/ja not_active Expired - Lifetime
- 2003-12-22 DK DK07009390T patent/DK1847539T3/da active
- 2003-12-22 DE DE60315892T patent/DE60315892T2/de not_active Expired - Lifetime
- 2003-12-22 PL PL377680A patent/PL221490B1/pl unknown
- 2003-12-22 US US10/539,220 patent/US7528121B2/en active Active
- 2003-12-22 WO PCT/GB2003/005613 patent/WO2004058781A1/en active Application Filing
- 2003-12-22 AT AT03782672T patent/ATE370958T1/de active
- 2003-12-22 MX MXPA05006918A patent/MXPA05006918A/es active IP Right Grant
- 2003-12-22 RU RU2007121850/04A patent/RU2350611C1/ru active
- 2003-12-22 DK DK03782672T patent/DK1578755T3/da active
- 2003-12-22 EP EP07009390A patent/EP1847539B1/en not_active Expired - Lifetime
- 2003-12-22 SI SI200330965T patent/SI1578755T1/sl unknown
- 2003-12-22 PT PT07009390T patent/PT1847539E/pt unknown
- 2003-12-22 AT AT07009390T patent/ATE438644T1/de active
- 2003-12-22 AU AU2003290313A patent/AU2003290313B2/en not_active Expired
- 2003-12-22 CA CA2511613A patent/CA2511613C/en not_active Expired - Lifetime
- 2003-12-22 ES ES07009390T patent/ES2329623T3/es not_active Expired - Lifetime
- 2003-12-22 MY MYPI20034944A patent/MY136174A/en unknown
- 2003-12-22 UA UAA200507294A patent/UA83814C2/ru unknown
- 2003-12-22 PT PT03782672T patent/PT1578755E/pt unknown
- 2003-12-22 PL PL412704A patent/PL223998B1/pl unknown
- 2003-12-22 RU RU2005123485/04A patent/RU2357971C2/ru active
- 2003-12-22 BR BRPI0317717A patent/BRPI0317717B8/pt active IP Right Grant
- 2003-12-22 CL CL200302731A patent/CL2003002731A1/es unknown
- 2003-12-23 TW TW092136601A patent/TWI336327B/zh not_active IP Right Cessation
- 2003-12-23 AR ARP030104824A patent/AR042668A1/es active IP Right Grant
- 2003-12-23 TW TW099134275A patent/TWI393710B/zh not_active IP Right Cessation
- 2003-12-23 UY UY28149A patent/UY28149A1/es not_active Application Discontinuation
-
2004
- 2004-02-18 SA SA04240504A patent/SA04240504B1/ar unknown
-
2005
- 2005-06-09 IL IL169112A patent/IL169112A/en active IP Right Grant
- 2005-06-13 NO NO20052855A patent/NO335193B1/no not_active IP Right Cessation
- 2005-07-20 IS IS7948A patent/IS2504B/is unknown
-
2006
- 2006-01-10 HK HK06100400A patent/HK1080481A1/xx not_active IP Right Cessation
-
2007
- 2007-05-16 AR ARP070102117A patent/AR057753A2/es not_active Application Discontinuation
- 2007-06-13 RU RU2007121850/04K patent/RU2007121850A/ru unknown
- 2007-06-28 JP JP2007169891A patent/JP4906608B2/ja not_active Expired - Lifetime
- 2007-08-09 IL IL185176A patent/IL185176A/en active IP Right Grant
- 2007-10-24 CY CY20071101369T patent/CY1107775T1/el unknown
-
2008
- 2008-02-13 IS IS8714A patent/IS2884B/is unknown
- 2008-02-27 HK HK08102177.3A patent/HK1111417A1/xx not_active IP Right Cessation
- 2008-10-15 JP JP2008265949A patent/JP4503090B2/ja not_active Expired - Lifetime
-
2009
- 2009-04-28 US US12/431,165 patent/US8268841B2/en active Active
- 2009-10-13 CY CY20091101054T patent/CY1109479T1/el unknown
-
2012
- 2012-08-21 US US13/590,662 patent/US9018191B2/en active Active
-
2013
- 2013-11-01 NO NO20131444A patent/NO335446B1/no not_active IP Right Cessation
-
2015
- 2015-03-18 US US14/661,657 patent/US9567358B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007121850A (ru) | Производные фосфонооксихиназолина и их фармацевтическое применение | |
GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
CZ305838B6 (cs) | N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6 | |
NO20033732L (no) | N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser. | |
MY142444A (en) | Chemokine receptor antagonists | |
CA2455050A1 (en) | Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof | |
HK1065540A1 (en) | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases | |
CO4410196A1 (es) | Antagonistas heterociclicos de receptores de taquicininas | |
RS20050046A (en) | 3-z-/1-(4-(n-((4-methyl-piperazin-1-yl)- methylcarbonyl)-n- methyl-amino)- anilino)-1-phenyl-methylene/-6- methoxycarbonyl -2-indolinone- monoethanesulphonate and the use thereof as a pharmaceutical composition | |
EP1741712A3 (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol | |
RS51444B (sr) | JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa | |
NO20014479D0 (no) | Fremgangsmåte ved behandling av spiseforstyrrelser | |
ATE394383T1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren | |
DE69718194T2 (de) | Amidinophenyl-pyrrolidine, -pyrroline und -isoxazolidine und ihre derivate | |
WO2003047520A3 (en) | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | |
MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
NO20040881L (no) | Orale antidiabetes midler. | |
IS7766A (is) | N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf | |
IS2473B (is) | Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess | |
IL177626A0 (en) | Pharmaceutical compositions for treating sleep apnoea | |
IL157540A0 (en) | N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof | |
EE200100520A (et) | N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena | |
MXPA01009469A (es) | Tratamiento para disminuir la adhesividad de las plaquetas. | |
MXPA01009468A (es) | Tratamiento de hipertension pulmonar. | |
DE60206782D1 (de) | Substituierte amide, sulfonamide und harnstoffe mit kinasehemmender wirkung |